![]() The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases. ![]() Specific details of the collaboration were not disclosed.īased in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. "We are undertaking together the largest protein study ever performed - over 200 million individual protein measurements - to gain substantial new knowledge about normal and disease biology across many common and rare conditions." "This collaboration with deCODE gives us an exciting opportunity to work with one of the most highly characterized and understood datasets in the world, as well as with world-class genomic and pharmaceutical scientists," said Stephen Williams, M.D., chief medical officer at SomaLogic. SomaLogic will use the assay results and related clinical information to further develop clinical applications of the SOMAscan assay in an effort to improve health management. deCODE will use the assay data for therapeutic drug discovery and development. Under the collaboration agreement, SomaLogic will analyze up to 40,000 deCODE samples with the proprietary SOMAscan® assay, which can rapidly measure the levels of 5,000 proteins in each sample across a wide range of concentrations. "SomaLogic's ability to measure thousands of proteins brings a whole new dimension to our efforts, and we look forward to seeing the results." Med., founder and chief executive officer of deCODE genetics. "I am excited to see what deep proteomic analysis will add to what we already know about human health based on our study of genetics," said Kári Stefánsson, M.D., Dr. The collaboration combines deCODE's rich data sets with SomaLogic's leading protein measurement capabilities to enhance the understanding of how human disease and health are mediated through proteins to influence health outcomes. today announced a collaboration that brings together SomaLogic's expertise in human proteins with deCODE's expertise in human genetics. 13, 2018 /PRNewswire/ - deCODE genetics, an Amgen subsidiary, and SomaLogic, Inc. REYKJAVIK, Iceland and BOULDER, Colo., Dec. Largest-ever Protein Measurement Study Enhances deCODE's Efforts in Basic Research, Drug Discovery and Novel Protein-based Diagnostics Clinical Trial Diversity and RepresentationĬlinical Trial Transparency, Data Sharing and Disclosure PracticesĪdverse Event and Product Complaint ReportingĮnvironmental, Social & Governance Report 2021Įnvironment, Social and Governance StrategyĬommunity Investment and Amgen Foundation ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |